eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Toxicology

Toxicity, Tricyclic Antidepressant

Author: Samara Soghoian, MD, Medical Toxicology Fellow, Bellevue Hospital Center, New York University School of Medicine
Coauthor(s): Christopher I Doty, MD, FAAEM, Assistant Professor of Emergency Medicine, Residency Program Director, Department of Emergency Medicine, Kings County Hospital Center, State University of New York Downstate Medical Center; Frank A Maffei, MD, FAAP, Associate Professor of Pediatrics, Temple University School of Medicine; Director of Medical Student Affairs, Geisinger Health System; Pediatric Critical Care Attending Physician, Janet Weis Children's Hospital at Geisinger Medical Center; Heidi Connolly, MD, Associate Professor of Pediatrics and Psychiatry, University of Rochester; Director, Pediatric Sleep Medicine Services, Strong Sleep Disorders Center
Contributor Information and Disclosures

Updated: Nov 19, 2008

Introduction

Background

Cyclic antidepressants (CAs) have been used in the treatment of major depression since the late 1950s. Originally termed tricyclic antidepressants (TCAs), they are now more accurately called cyclic antidepressants because some newer members of this class have a 4-ring structure. They are also currently used in the treatment of chronic pain syndromes and for migraine prophylaxis. In the pediatric population, they are commonly prescribed for the treatment of enuresis, obsessive-compulsive disorder, attention deficit hyperactivity disorder, school phobia, and separation anxiety. The most commonly prescribed cyclic antidepressants include amitriptyline, desipramine, imipramine, nortriptyline, doxepin, and clomipramine.

Cyclic antidepressants have a narrow therapeutic window, increasing their likelihood for toxicity. The clinical features of cyclic overdose were first reported in 1959, only 2 years after they began to be used clinically. In the past decade, the prescription of selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression has far surpassed that of cyclic antidepressants. However, the incidence of cyclic antidepressant toxicity is currently on the rise due to changes in prescribing practices, and increasing interest in the therapeutic potential of cyclic antidepressants for chronic pain syndromes. Cyclic antidepressants remain second only to analgesics as the most common drugs implicated in overdose fatalities. Some evidence suggests that cyclic antidepressants are associated with more overdose fatalities per number of prescriptions issued than other antidepressant classes.

Pathophysiology

Cyclic antidepressants are named for their 3-ring or 4-ring aromatic (heterocyclic) structure. They are rapidly absorbed in the GI tract and undergo first-pass metabolism in the liver. Conjugates are then renally eliminated. Cyclic antidepressants are very lipophilic and highly protein-bound, leading to large volumes of distribution. They have long elimination half-lives that often exceed 24 hours (>31-46 h for amitriptyline). In an overdose, altered pharmacokinetics may prolong elimination and increase toxic effects. Cyclic antidepressants have significant anticholinergic effects that can delay gastric emptying. Additionally, the acidosis that results from respiratory depression and hypotension reduces protein-binding, resulting in higher serum levels of active free drug.

Although the exact therapeutic mechanism of cyclic antidepressants is not known, it is most likely related to decreased central norepinephrine and serotonin reuptake, resulting in increased levels of these biogenic amines in the brain. The therapeutic dose for most cyclic antidepressants in children is 5-10 mg/kg/d, and toxicity may be observed at doses of 10-20 mg/kg/d. Significant adverse effects are generally seen only with doses greater than 20 mg/kg/d. The toxic effects of cyclic antidepressants are related to the following 4 pharmacologic effects:

  • Anticholinergic effects
  • Direct alpha-adrenergic blockade
  • Inhibition of norepinephrine and serotonin reuptake
  • Blockade of fast sodium channels in myocardial cells, resulting in quinidinelike membrane-stabilizing effects

The most serious adverse effects of cyclic antidepressant toxicity are due to CNS effects and cardiovascular instability. Depressed mental status is generally caused by the antihistamine and anticholinergic properties of cyclic antidepressants, whereas seizures are thought to be due to increased CNS levels of biogenic amines. Life-threatening cardiovascular complications are due to impaired conduction from fast sodium channel blockade. This decreases the slope of phase zero depolarization, widens the QRS complex, and prolongs the PR and QT intervals. Impaired cardiac conduction may lead to heart block and unstable ventricular arrhythmias or asystole. cyclic antidepressants have also been shown to directly depress myocardial contractility. However, the profound hypotension seen in serious cyclic antidepressant poisoning is primarily due to vasodilatation from direct alpha-adrenergic blockade.

Frequency

United States

The 2004 American Association of Poison Control Centers (AAPCC) annual report on toxic exposures in the United States included 103,155 reported cases of antidepressant toxicity; 12,269 were due to heterocyclic agents, with a total of 86 deaths.1 Cyclic antidepressants poisoning was reported in 2,948 children. Of these cases, 1,355 occurred in children younger than 6 years, while another 1,593 occurred in children aged 6-19 years.

Among antidepressant agents, cyclic antidepressants were the third most common class implicated in toxic exposures. SSRIs were the most common antidepressants taken in toxic doses. This is most likely due to the frequency with which they are prescribed.

Mortality/Morbidity

Cyclic antidepressants toxicity accounts for approximately 12% of reported toxic exposures for antidepressants but accounts for approximately 29% of deaths due to antidepressant poisoning. cyclic antidepressants were the most common cause of overdose-related fatalities until the past decade, when analgesics surpassed them as a class.

Sex

The incidence of cyclic antidepressants poisoning is higher in women than in men. This most likely reflects a higher rate of depression and suicide attempts among women.

Age

The distribution of toxic cyclic antidepressant exposures in children is bimodal, with peaks in early childhood and the later teenaged years. Accidental exposure is typically seen in toddlers, whereas adolescents tend to present with intentional overdoses.

Clinical

History

The history in patients with cyclic antidepressant (CA) poisoning may include either intentional or unintentional ingestion. Older children should be screened for suicidal ideation and prior self-harm.

  • An attempt should be made to determine the specific agent ingested because the toxic profiles of different cyclic antidepressants may vary. For example, amoxapine is associated with a higher incidence of seizures, whereas maprotiline is more likely to be cardiotoxic. Both dothiepin and amitriptyline have been shown to have greater toxicity than the other cyclic antidepressants.
  • Patients and their families should be questioned as to the dose and time of ingestion. Onset of symptoms typically occurs within 2 hours, and major complications typically occur within the first 6 hours after exposure.
  • Determine if any co-ingestions have occurred.

Physical

Physical examination findings relate to the anticholinergic, cardiovascular, and CNS effects of cyclic antidepressants. Anticholinergic effects are typically the first to appear and should raise clinical suspicion of cyclic antidepressant overdose. Recently, a sodium channel blockade toxidrome has been proposed and described, using the mnemonic "S-A-L-T" (ie, shock, altered mental status, long-QRS interval duration, terminal R wave in aVR).2

  • Anticholinergic effects may include the following:
    • Xerostomia
    • Blurred vision, mydriasis
    • Urinary retention
    • Hypoactive or absent bowel sounds
    • Pyrexia
    • Myoclonic twitching
  • Cardiovascular effects may include the following:
    • Sinus tachycardia
    • Prolonged PR, QRS, and QT intervals
    • Heart block
    • Peripheral vasodilatation
    • Hypotension
    • Cardiogenic shock
    • Ventricular arrhythmias
    • Asystole
  • CNS effects may include the following:
    • Drowsiness
    • Extrapyramidal signs
    • Rigidity
    • Ophthalmoplegia
    • Respiratory depression
    • Delirium
    • Seizure
    • Coma

More on Toxicity, Tricyclic Antidepressant

Overview: Toxicity, Tricyclic Antidepressant
Differential Diagnoses & Workup: Toxicity, Tricyclic Antidepressant
Treatment & Medication: Toxicity, Tricyclic Antidepressant
Follow-up: Toxicity, Tricyclic Antidepressant
References

References

  1. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. Sep 2005;23(5):589-666. [Medline].

  2. Lester L, McLaughlin S. SALT: a case for the sodium channel blockade toxidrome and the mnemonic SALT. Ann Emerg Med. Feb 2008;51(2):214. [Medline].

  3. Bailey B, Buckley NA, Amre DK. A meta-analysis of prognostic indicators to predict seizures, arrhythmias or death after tricyclic antidepressant overdose. J Toxicol Clin Toxicol. 2004;42(6):877-88. [Medline].

  4. Liebelt EL, Ulrich A, Francis PD, Woolf A. Serial electrocardiogram changes in acute tricyclic antidepressant overdoses. Crit Care Med. Oct 1997;25(10):1721-6. [Medline].

  5. Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. Aug 1995;26(2):195-201. [Medline].

  6. Kulig K, Bar-Or D, Cantrill SV, Rosen P, Rumack BH. Management of acutely poisoned patients without gastric emptying. Ann Emerg Med. Jun 1985;14(6):562-7. [Medline].

  7. Heard K, Dart RC, Bogdan G, et al. A preliminary study of tricyclic antidepressant (TCA) ovine FAB for TCA toxicity. Clin Toxicol (Phila). 2006;44(3):275-81. [Medline].

  8. Banks CJ, Furyk JS. Review article: Hypertonic saline use in the emergency department. Emerg Med Australas. May 6 2008;[Medline].

  9. Algren DA, Sutter ME. Treatment of tricyclic antidepressant cardiac toxicity. Pediatr Emerg Care. Mar 2008;24(3):199. [Medline].

  10. Boehnert MT, Lovejoy FH Jr. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med. Aug 22 1985;313(8):474-9. [Medline].

  11. Callaham M, Kassel D. Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Ann Emerg Med. Jan 1985;14(1):1-9. [Medline].

  12. Chyka PA, Seger D. Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1997;35(7):721-41. [Medline].

  13. Ellenhorn MJ. Ellenhorn's Medical Toxicology. 2nd ed. Baltimore, MD: Williams & Wilkins; 1997:624-36.

  14. Farrar HC, James LP. Characteristics of pediatric admissions for cyclic antidepressant poisoning. Am J Emerg Med. Sep 1999;17(5):495-6. [Medline].

  15. Weisman RS, Goldfrank LR, Flomenbaum NE, eds. Goldfrank's Toxicologic Emergencies. 6th ed. McGraw-Hill Professional; 1998:925-33.

  16. Goodwin DA, Lally KP, Null DM Jr. Extracorporeal membrane oxygenation support for cardiac dysfunction from tricyclic antidepressant overdose. Crit Care Med. Apr 1993;21(4):625-7. [Medline].

  17. James LP, Kearns GL. Cyclic antidepressant toxicity in children and adolescents. J Clin Pharmacol. Apr 1995;35(4):343-50. [Medline].

  18. Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J. Jul 2001;18(4):236-41. [Medline].

  19. Liebelt EL, DeAngelis CD. Evolving trends and treatment advances in pediatric poisoning. JAMA. Sep 22-29 1999;282(12):1113-5. [Medline].

  20. Liebelt EL, Shanon M. Targeted management strategies for cardiovascular toxicity from tricyclic antidepressant overdose: the pivotal role for alkalinization and sodium loading. Pediatr Emerg Care. Aug 1998;14(4):293-8. [Medline].

  21. Newton EH, Shih RD, Hoffman RS. Cyclic antidepressant overdose: a review of current management strategies. Am J Emerg Med. May 1994;12(3):376-9. [Medline].

  22. Pentel PR, Keyler DE. Clinical Management of Poisoning and Drug Overdose. 3rd ed. Philadelphia, PA: WB Saunders Co; 1998:437-49.

  23. Pimentel L, Trommer L. Cyclic antidepressant overdoses. A review. Emerg Med Clin North Am. May 1994;12(2):533-47. [Medline].

  24. Reith D, Fountain J, Tilyard M, McDowell R. Antidepressant poisoning deaths in New Zealand for 2001. N Z Med J. Oct 24 2003;116(1184):U646. [Medline].

  25. Teba L, Schiebel F, Dedhia HV, Lazzell VA. Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose. Am J Emerg Med. Nov 1988;6(6):566-8. [Medline].

  26. Tenenbein M. Position statement: whole bowel irrigation. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1997;35(7):753-62. [Medline].

  27. Vale JA. Position statement: gastric lavage. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1997;35(7):711-9. [Medline].

Further Reading

Keywords

cyclic antidepressant, cyclic antidepressant toxicity, CA toxicity, CA overdose, CA poisoning, CA, tricyclic antidepressant toxicity, TCA, TCA overdose, TCA toxicity, TCA poisoning, antidepressant overdose, antidepressant toxicity, antidepressant poisoning, chronic pain syndromes, migraine prophylaxis, enuresis, obsessive-compulsive disorder, attention-hyperactivity disorder, school phobia, separation anxiety, depression, overdose, seizures, suicide attempts, amitriptyline, desipramine, imipramine, nortriptyline, doxepin, clomipramine, myoclonic twitching, heart block, hypotension, cardiogenic shock, drowsiness, rigidity, respiratory depression, delirium

Contributor Information and Disclosures

Author

Samara Soghoian, MD, Medical Toxicology Fellow, Bellevue Hospital Center, New York University School of Medicine
Samara Soghoian, MD is a member of the following medical societies: American College of Medical Toxicology and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Christopher I Doty, MD, FAAEM, Assistant Professor of Emergency Medicine, Residency Program Director, Department of Emergency Medicine, Kings County Hospital Center, State University of New York Downstate Medical Center
Christopher I Doty, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Frank A Maffei, MD, FAAP, Associate Professor of Pediatrics, Temple University School of Medicine; Director of Medical Student Affairs, Geisinger Health System; Pediatric Critical Care Attending Physician, Janet Weis Children's Hospital at Geisinger Medical Center
Frank A Maffei, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Heidi Connolly, MD, Associate Professor of Pediatrics and Psychiatry, University of Rochester; Director, Pediatric Sleep Medicine Services, Strong Sleep Disorders Center
Heidi Connolly, MD is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, and Society of Critical Care Medicine
Disclosure: Nothing to disclose.

Medical Editor

Michael E Mullins, MD, Assistant Professor, Department of Emergency Medicine, Washington University School of Medicine
Michael E Mullins, MD is a member of the following medical societies: American Academy of Clinical Toxicology and American College of Emergency Physicians
Disclosure: Johnson & Johnson stock ownership None; Savient Pharmaceuticals stock ownership None

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Jeffrey R Tucker, MD, Assistant Professor, Department of Pediatrics, Division of Emergency Medicine, University of Connecticut and Connecticut Children's Medical Center
Jeffrey R Tucker, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Pediatrics, and Massachusetts Medical Society
Disclosure: Merck Salary Employment

CME Editor

Paul D Petry, DO, FACOP, FAAP, Consulting Staff, Freeman Pediatric Care, Freeman Health System
Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association
Disclosure: Nothing to disclose.

Chief Editor

Timothy E Corden, MD, Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin
Timothy E Corden, MD is a member of the following medical societies: American Academy of Pediatrics, Phi Beta Kappa, Society of Critical Care Medicine, and Wisconsin Medical Society
Disclosure: Nothing to disclose.

RELATED INFORMATION FROM INDUSTRY
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.